Premium
Therapeutic oophorectomy in metastatic breast cancer
Author(s) -
Conte Charles C.,
Nemoto Takuma,
Rosner Dutzu,
Dao Thomas L.
Publication year - 1989
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19890701)64:1<150::aid-cncr2820640125>3.0.co;2-n
Subject(s) - oophorectomy , medicine , metastatic breast cancer , breast cancer , cancer , hysterectomy , surgery , gynecology , oncology
One hundred five patients undergoing therapeutic oophorectomy for metastatic breast cancer (n = 105) from 1975 to 1985 were reviewed. There were 54 responders (51%) to oophorectomy, with a median duration of response of 16 months (range, 3 to 129 months). Thirty of 42 (71%) estrogen receptor (ER)‐positive patients responded to oophorectomy versus five of 24 (21%) ER‐negative patients ( P < 0.001). Of the 39 patients with unknown ER status, 19 (49%) responded to oophorectomy. Osseous, soft tissue, and pulmonary metastases responded at similar rates. Of the 16 patients who had received adjuvant chemotherapy, there were five responders (31%) to oophorectomy. Second‐line endocrine therapy was effective in 29 of 53 (55%) patients. Fifteen of 28 (54%) ER‐positive patients responded to second‐line endocrine therapy while two of six (33%) ER‐negative patients responded. Twenty‐three of 37 (62%) oophorectomy responders responded to second‐line endocrine therapy versus six of 16 (38) nonresponders. Oophorectomy appears to be a valuable palliative treatment for metastatic breast cancer. ER‐positive patients have the best chance of responding to this therapy. However, ER‐negative patients have a reduced but definite chance of responding with a good duration of response. Response to further endocrine treatments is predicted by response to oophorectomy and to a lesser degree by ER status.